Genentech

Phesgo

Manufacturer:

Genentech

Phesgo HCPCS:

J9316

HCPCS Code Descriptor:

Injection, pertuzumab, trastuzumab, and hyaluronidase-zzxf, per 10 mg

Category:

J Code

Phesgo NDCs:

50242-0245-01, 50242-0260-01

Primary Type:

Oncology

Generic/Specialty Status:

Single-Source

Package Type:

Vial

Route of Administration:

Subcutaneous

Phesgo CPT Codes:

Potential CPT administration codes for Phesgo can be found at the following link.

Potential NDC Listing Errors:

Our team did not identify any potential listing errors/discrepancies for the NDCs mapped to this HCPCS code.

About Phesgo:

Phesgo is an Oncology drug manufactured by Genentech and administered via the Subcutaneous route of administration. The J Code: J9316 is aligned to the drug Phesgo.

ACCESS PRICING AND MORE BY REGISTERING

J9316 Added Date:

January 1, 2021

J9316 Effective Date:

January 1, 2021

J9316 Termination Date:

HCPCS Active

Phesgo billing and coding information can be found through Genentech at the link below:
Phesgo patient assistance information can be found through Genentech at the URL: https://www.gene.com/patients/patient-foundation
Phesgo prescribing information can be found at the link below:
Information regarding Phesgo’s side effects can be found at MedlinePlus